{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:45:21Z","timestamp":1785908721993,"version":"3.56.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Autoimmune hepatitis (AIH) is a chronic inflammatory liver disease treated with glucocorticoids (GCs). Long-term GCs therapy may increase the risk of hepatic steatosis. This study aimed to evaluate the impact of prolonged GCs therapy on hepatic steatosis in patients with AIH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed patients with AIH treated at a single center from January 2017 to December 2023. Eligible patients had received systemic GCs therapy for at least 24 months and had at least one paired assessment of hepatic steatosis before and after treatment, including liver histology, CAP, or abdominal ultrasound.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 160 patients, 43 (26.88%) developed new-onset or progressive hepatic steatosis. CAP values increased by 24.34 dB\/m, and ultrasound-detected steatosis prevalence rose from 21.28% to 42.55%. Elevated triglyceride levels at 6 months were independently associated with new-onset or progressive hepatic steatosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Long-term GCs therapy was associated with a measurable increase in hepatic steatosis in patients with AIH across complementary assessment modalities. Six-month triglyceride levels may serve as an early metabolic marker for identifying patients at increased risk, supporting dynamic metabolic and steatosis monitoring during long-term immunosuppressive treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1891955","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:55:13Z","timestamp":1785905713000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Development and progression of hepatic steatosis during long-term glucocorticoid therapy in autoimmune hepatitis: multimodal evidence from biopsy, CAP, and ultrasound"],"prefix":"10.3389","volume":"13","author":[{"given":"Yijun","family":"Bao","sequence":"first","affiliation":[{"name":"Nanjing University of Chinese Medicine","place":["Nanjing, China"]},{"name":"Department of Infectious Diseases and Hepatology, the Second Hospital of Nanjing, Affiliated with Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine","place":["Nanjing, China"]},{"name":"Department of Infectious Diseases and Hepatology, the Second Hospital of Nanjing, Affiliated with Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, the Second Hospital of Nanjing, Affiliated with Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongfeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, the Second Hospital of Nanjing, Affiliated with Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8278173","DOI":"10.1016\/j.jhep.2025.03.017","article-title":"EASL clinical practice guidelines on the management of autoimmune hepatitis","year":"2025","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatol Baltim Md."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/rheumatology\/keae204","article-title":"Risk of diabetes mellitus in systemic lupus erythematosus: systematic review and meta-analysis","volume":"63","author":"Etchegaray-Morales","year":"2024","journal-title":"Rheumatol Oxf Engl."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/rheumatology\/keab548","article-title":"Low-dose oral glucocorticoid therapy and risk of osteoporotic fractures in patients with rheumatoid arthritis: a cohort study using the clinical practice research datalink","volume":"61","author":"Abtahi","year":"2022","journal-title":"Rheumatol Oxf Engl."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1080\/17474124.2021.1952867","article-title":"Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction","volume":"15","author":"Gaber","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MCG.0000000000001817","article-title":"Patients with autoimmune hepatitis and nonalcoholic fatty liver disease: characteristics, treatment, and outcomes","volume":"58","author":"Strzepka","year":"2024","journal-title":"J Clin Gastroenterol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1007\/s12072-024-10727-w","article-title":"Liver fibrosis is closely linked with metabolic-associated diseases in patients with autoimmune hepatitis","volume":"18","author":"Liu","year":"2024","journal-title":"Hepatol Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1040029","DOI":"10.3389\/fimmu.2022.1040029","article-title":"Impact of hepatic steatosis on treatment response of autoimmune hepatitis: a retrospective multicentre analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3748\/wjg.v27.i1.80","article-title":"Evaluation of controlled attenuation parameter in assessing hepatic steatosis in patients with autoimmune liver diseases","volume":"27","author":"Ni","year":"2021","journal-title":"World J Gastroenterol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jhep.2016.12.022","article-title":"Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis","volume":"66","author":"Karlas","year":"2017","journal-title":"J Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"6662760","DOI":"10.1155\/2021\/6662760","article-title":"Controlled attenuation parameter for quantification of steatosis: which cut-offs to use?","volume":"2021","author":"Sirli","year":"2021","journal-title":"Can J Gastroenterol Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clinre.2011.08.001","article-title":"The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using fibroscan","volume":"36","author":"Sasso","year":"2012","journal-title":"Clin Res Hepatol Gastroenterol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e0182784","DOI":"10.1371\/journal.pone.0182784","article-title":"A prospective comparative assessment of the accuracy of the FibroScan in evaluating liver steatosis","volume":"12","author":"Jun","year":"2017","journal-title":"PLoS ONE."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology."},{"key":"B16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update","volume":"75","year":"2021","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3899\/jrheum.160214","article-title":"Cumulative burden of glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study","volume":"45","author":"Chen","year":"2018","journal-title":"J Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/jbmr.3523","article-title":"Glucocorticoid exposure and fracture risk in a cohort of US patients with selected conditions","volume":"33","author":"Balasubramanian","year":"2018","journal-title":"J Bone Miner Res Off J Am Soc Bone Miner Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e001220","DOI":"10.1136\/bmjdrc-2020-001220","article-title":"Glucocorticoid dose-dependent risk of type 2 diabetes in six immune-mediated inflammatory diseases: a population-based cohort analysis","volume":"8","author":"Wu","year":"2020","journal-title":"BMJ Open Diabetes Res Care."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/apt.15528","article-title":"Adverse events related to low dose corticosteroids in autoimmune hepatitis","volume":"50","author":"van den Brand","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/apt.17191","article-title":"Autoimmune hepatitis and metabolic syndrome-associated disease development: A U","volume":"56","author":"Jalal","year":"2022","journal-title":"S cohort study Aliment Pharmacol Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12986-018-0272-0","article-title":"Neonatal overfeeding induced glucocorticoid overexposure accelerates hepatic lipogenesis in male rats","volume":"15","author":"Yang","year":"2018","journal-title":"Nutr Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1016\/j.celrep.2018.02.041","article-title":"Estrogen deficiency promotes hepatic steatosis via a glucocorticoid receptor-dependent mechanism in mice","volume":"22","author":"Quinn","year":"2018","journal-title":"Cell Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"13776","DOI":"10.1038\/s41598-021-93378-3","article-title":"Chronic glucocorticoid treatment induces hepatic lipid accumulation and hyperinsulinaemia in part through actions on AgRP neurons","volume":"11","author":"Harno","year":"2021","journal-title":"Sci Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12876-022-02242-9","article-title":"Steroid-mediated liver steatosis is CD1d-dependent, while steroid-induced liver necrosis, inflammation, and metabolic changes are CD1d-independent","volume":"22","author":"Adar","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s10654-022-00868-3","article-title":"Lifestyle and metabolic factors for nonalcoholic fatty liver disease: mendelian randomization study","volume":"37","author":"Yuan","year":"2022","journal-title":"Eur J Epidemiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/hep.32728","article-title":"The associations between modifiable risk factors and nonalcoholic fatty liver disease: a comprehensive mendelian randomization study","volume":"77","author":"Xie","year":"2023","journal-title":"Hepatol Baltim Md."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2480250","DOI":"10.1080\/07853890.2025.2480250","article-title":"Lipid profile and non-alcoholic fatty liver disease detected by ultrasonography: is systemic inflammation a necessary mediator?","volume":"57","author":"Li","year":"2025","journal-title":"Ann Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"691556","DOI":"10.3389\/fendo.2021.691556","article-title":"Varied relationship of lipid and lipoprotein profiles to liver fat content in phenotypes of metabolic associated fatty liver disease","volume":"12","author":"Wu","year":"2021","journal-title":"Front Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3390\/nu13020552","article-title":"Implication between genetic variants from APOA5 and ZPR1 and NAFLD severity in patients with hypertriglyceridemia","volume":"13","author":"Esteve-Luque","year":"2021","journal-title":"Nutrients."},{"key":"B31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat Genet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jhep.2018.06.024","article-title":"EASL clinical practice guidelines on nutrition in chronic liver disease","volume":"70","year":"2019","journal-title":"J Hepatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"7653689","DOI":"10.1155\/2016\/7653689","article-title":"Associations between white blood cell count and the development of incidental nonalcoholic fatty liver disease","volume":"2016","author":"Chung","year":"2016","journal-title":"Gastroenterol Res Pract."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e010342","DOI":"10.1136\/bmjopen-2015-010342","article-title":"Association between white blood cell count and non-alcoholic fatty liver disease in urban han chinese: a prospective cohort study","volume":"6","author":"Wang","year":"2016","journal-title":"BMJ Open."},{"key":"B35","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3390\/biomedicines10040892","article-title":"Hepatic steatosis is associated with high white blood cell and platelet counts","volume":"10","author":"Chao","year":"2022","journal-title":"Biomedicines."},{"key":"B36","doi-asserted-by":"publisher","first-page":"760981","DOI":"10.3389\/fendo.2021.760981","article-title":"Red blood cell count: an unrecognized risk factor for nonalcoholic fatty liver disease","volume":"12","author":"Zhong","year":"2021","journal-title":"Front Endocrinol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/MPG.0000000000001614","article-title":"Elevated hemoglobin level is associated with advanced fibrosis in pediatric nonalcoholic fatty liver disease","volume":"65","author":"Giorgio","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"B38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.dld.2016.10.004","article-title":"Associations between hemoglobin concentrations and the development of incidental metabolic syndrome or nonalcoholic fatty liver disease","volume":"49","author":"Chung","year":"2017","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e0279274","DOI":"10.1371\/journal.pone.0279274","article-title":"Associations between red blood cell count and metabolic dysfunction-associated fatty liver disease (MAFLD)","volume":"17","author":"Dai","year":"2022","journal-title":"PLoS ONE."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1111\/jcmm.14845","article-title":"Increased proliferation of hepatic periportal ductal progenitor cells contributes to persistent hypermetabolism after trauma","volume":"24","author":"Diao","year":"2020","journal-title":"J Cell Mol Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1097\/QAD.0000000000003351","article-title":"Controlled attenuation parameter accurately detects liver steatosis in people with HIV","volume":"36","author":"Duarte","year":"2022","journal-title":"AIDS Lond Engl."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1002\/ueg2.70099","article-title":"Marked variation in hepatic steatosis in metabolic dysfunction-associated steatotic liver disease over 5 years: a community-based study using controlled attenuation parameter","volume":"13","author":"Cervera","year":"2025","journal-title":"United Eur Gastroenterol J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"100778","DOI":"10.1016\/j.jhepr.2023.100778","article-title":"Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease","volume":"5","author":"Zachou","year":"2023","journal-title":"JHEP Rep Innov Hepatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1891955\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:55:28Z","timestamp":1785905728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1891955\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":43,"alternative-id":["10.3389\/fmed.2026.1891955"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1891955","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1891955"}}